Biotec Services International Completes its Rebrand into PCI Group
News Feb 12, 2015
PCI has announced that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group.
This rebrand brings together the expertise of two world class organizations and significantly expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products.
The broad range of services includes, manufacturing, packaging and labelling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for optimal clinical package design, global logistics planning and depot management over a wide range of temperatures from controlled ambient to -196°C, a service for which Biotec is known across the globe.
Dr Fiona Withey, Managing Director, UK Clinical Services, stated “The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization.”
Biotec recently announced the completion of an expansion to it Bridgend facilities. This development significantly expands the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain expertise solutions - supporting medicines from +25°C down to -196°C.
The enhanced Bridgend facilities are an important part of PCI’s network of sites encompassing both Europe and North America, providing clinical and commercial medicines to over 100 countries globally.
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE